You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2024

Claims for Patent: 7,727,552


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,727,552
Title:Oral pharmaceutical preparations decreased in bitterness by masking
Abstract:A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.
Inventor(s): Ukai; Koji (Gifu, JP), Hrada; Tsutomu (Aichi, JP), Suzuki; Yasuyuki (Gifu, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:09/380,310
Patent Claims: 1. An oral medicine preventing an unpleasant taste which comprises a mixture comprising a basic medicine having an unpleasant taste and an acidic polysaccharide, wherein the mixture is in a homogeneous blend and said basic medicine and acidic polysaccharide are in intimate contact in order to form an electric interaction and to prevent the basic medicine from dissolving in saliva; said homogeneous blend further comprises a filler, a binding agent or disintegrant, or both a filler and a disintegrant; said medicine is in the form of granules or fine granules for oral administration or a tablet for oral administration comprising the homogeneous blend; said acidic polysaccharide is at least one member selected from the group consisting of carrageenan and salts thereof; said acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste, and said basic medicine is donepezil hydrochloride.

2. A method for manufacturing an oral medicine in the form of granules or fine granules for oral administration or a tablet for oral administration, said medicine comprising a mixture comprising basic medicine having an unpleasant taste and an acidic polysaccharide, said method comprising: blending the mixture to obtain a homogeneous blend of said oral medicine; wherein said acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic medicine; and forming the mixture comprising the homogeneous blend into granules, fine granules or a tablet for oral administration, wherein said basic medicine and acidic polysaccharide are in intimate contact in order to form an electric interaction and to prevent the basic medicine from dissolving in saliva; wherein said homogeneous blend further comprises a filler, a disintegrant, or both a filler and a disintegrant to obtain said homogeneous blend; wherein said acidic polysaccharide is at least one member selected from the group consisting of carrageenan and salts thereof; and wherein said basic medicine is donepezil hydrochloride.

3. The oral medicine of claim 1, wherein the carrageenan is at least one member selected from the group consisting of -carrageenan, .kappa.-carrageenan, .lamda.-carrageenan, and a salt thereof.

4. The method of claim 2, wherein the carrageenan is at least one member selected from the group consisting of -carrageenan, .kappa.-carrageenan, .lamda.-carrageenan, and a salt thereof.

5. An oral medicine preventing an unpleasant taste which comprises a mixture comprising a basic medicine having an unpleasant taste and an acidic polysaccharide, wherein the mixture is in a homogeneous blend and said basic medicine and acidic polysaccharide are in intimate contact in order to form an electric interaction and to prevent the basic medicine from dissolving in saliva; said homogeneous blend further comprises a filler, a binding agent or disintegrant, or both a filler and a disintegrant; said medicine is in the form of granules or fine granules for oral administration or a tablet for oral administration comprising the homogeneous blend; said acidic polysaccharide is at least one member selected from the group consisting of chondroitin sulfate, dextran sulfate, and salts thereof; said acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic substance having the unpleasant taste, and said basic medicine is donepezil hydrochloride.

6. A method for manufacturing an oral medicine in the form of granules or fine granules for oral administration or a tablet for oral administration, said medicine comprising a mixture comprising basic medicine having an unpleasant taste and an acidic polysaccharide, said method comprising: blending the mixture to obtain a homogeneous blend of said oral medicine; wherein said acidic polysaccharide is in an amount of 0.1 to 20 parts by weight with respect to 1 part by weight of the basic medicine; and forming the mixture comprising the homogeneous blend into granules, fine granules or a tablet for oral administration, wherein said basic medicine and acidic polysaccharide are in intimate contact in order to form an electric interaction and to prevent the basic medicine from dissolving in saliva; wherein said homogeneous blend further comprises a filler, a disintegrant, or both a filler and a disintegrant to obtain said homogeneous blend; wherein said acidic polysaccharide is at least one member selected from the group consisting of chondroitin sulfate, dextran sulfate, and salts thereof; and wherein said basic medicine is donepezil hydrochloride.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.